Autofits

Autofits logo
Menu

EU GMP Annex 1 Explained: Sterile Manufacturing, CCS and Vial Closure Integrity

EU GMP Annex 1 Explained: Sterile Manufacturing, CCS and Vial Closure Integrity

EU GMP Annex 1 is the European Union’s Good Manufacturing Practice guideline for the manufacture of sterile medicinal products. It sets out how sterile drugs, including injectables filled into vials, must be made to control microbial, particulate, and pyrogen contamination. The current version is the 2022 revision, which came into operation in 2023 (with one provision following in 2024) and is published within EudraLex Volume 4 by the European Commission. For anyone working with vial closures, the key point is that Annex 1 treats container closure integrity (CCI) as part of sterility assurance, and it expects every filled container to be inspected individually for defects.

This guide explains what Annex 1 is, what it requires around contamination control and CCI, why capping and sealing of vials matters under the guideline, and what it means for closure suppliers even though Annex 1 binds the drug manufacturer.

Key takeaways

  • EU GMP Annex 1 is the EU GMP guideline for sterile medicinal products, part of EudraLex Volume 4; the current 2022 revision came into operation in 2023.
  • It requires every manufacturer of sterile products to build a Contamination Control Strategy (CCS): a documented, site-wide plan to control microbial, particulate, and endotoxin contamination.
  • Quality Risk Management (QRM) underpins the whole guideline, aligned with the ICH Q9 framework.
  • Container closure integrity (CCI) is treated as part of sterility assurance: a vial is only sterile if its closure system actually keeps the sterile barrier intact.
  • Annex 1 sets expectations for vial capping control and individual inspection of every filled container, because a missing or displaced stopper or a defective seal is a recognised integrity risk.
  • Annex 1 legally binds the drug manufacturer, not the packaging supplier, but the closures supplied (stopper plus aluminium seal) are what the manufacturer relies on to meet it.

What is EU GMP Annex 1?

EU GMP Annex 1, “Manufacture of Sterile Medicinal Products,” is an annex to the EU Good Manufacturing Practice guidelines that sets the requirements for making sterile drugs. It is published by the European Commission as part of EudraLex Volume 4, the volume that contains the EU GMP guidelines for medicinal products for human and veterinary use.

Sterile medicinal products include injectables, eye preparations, and other dosage forms that must be free of viable microorganisms and controlled for particulates and endotoxins. Because contamination of a sterile product can directly harm a patient, Annex 1 is one of the most detailed and demanding parts of EU GMP.

The guideline was substantially rewritten in the 2022 revision, which came into operation on 25 August 2023, with the provision on lyophilisation following on 25 August 2024. The revision modernised expectations around contamination control, barrier technologies (such as isolators and restricted access barrier systems), and the formal use of risk management. Although it is an EU guideline, Annex 1 is widely referenced beyond Europe and has been adopted or recognised by other authorities, including through the PIC/S GMP guide, which mirrors it.

Contamination Control Strategy (CCS)

A Contamination Control Strategy is a documented, facility-wide plan that defines how a manufacturer controls every source of microbial, particulate, and endotoxin contamination, and Annex 1 makes it a central requirement. Rather than treating cleanliness as a set of isolated rules, the CCS asks a manufacturer to map all the points where contamination could enter the process and show how each is controlled and verified.

A CCS typically considers the facility and equipment design, personnel and gowning, utilities (such as water and gases), raw materials and primary packaging components, the manufacturing and filling process, and the monitoring that confirms control. Primary packaging belongs in the CCS because the vial, stopper, and seal are in direct contact with the sterile product and must be received, handled, and applied without compromising sterility. The closure is one of the contamination-control elements the strategy has to account for.

Quality Risk Management under Annex 1

Annex 1 is built on Quality Risk Management: decisions about facility design, processes, and controls must be justified by a documented assessment of risk to product quality and patient safety. QRM runs through the entire guideline rather than sitting in a single section.

This aligns with the wider pharmaceutical risk framework set out in ICH Q9, Quality Risk Management. In practice, it means a manufacturer must be able to explain why each control exists and how it manages a specific risk, including the risks associated with the container closure system. Selecting a closure, qualifying it, and confirming that the capping process produces an intact seal are all risk-based activities the manufacturer is expected to document.

Container closure integrity (CCI) and sterility assurance

Annex 1 treats container closure integrity as part of sterility assurance, because a product is only sterile for its shelf life if the closure keeps the sterile barrier intact. Sterilising or aseptically filling a product is not enough on its own. If the seal leaks, the sterile barrier fails and the product can be recontaminated.

A vial’s closure system has two main parts: the elastomeric stopper that seats in the vial neck and the aluminium or aluminium-plastic seal that is crimped over the stopper to hold it in place. The crimp is what maintains the compression on the stopper that keeps the container closed. If the seal is missing, loose, or damaged, that compression can be lost and integrity is at risk.

Annex 1 expects integrity to be assured and verified. Container closure integrity is commonly evaluated using the methods described in USP General Chapter <1207>, which covers package integrity evaluation for sterile products and distinguishes deterministic leak tests (such as vacuum decay and helium leak detection) from probabilistic methods. For a fuller treatment of those methods, see our guides to USP <1207> package integrity and container closure integrity testing methods.

Why vial capping and sealing matters under Annex 1

Annex 1 identifies capping of filled vials as a step that can affect integrity, and it expects vials with missing or displaced stoppers to be rejected before capping and every filled container to be inspected individually for defects. Capping is the operation that crimps the aluminium seal over the stopper. Done correctly, it locks the closure system and gives the vial its tamper-evident, integrity-maintaining finish.

Under the Annex 1 capping provisions, vials with missing or displaced stoppers must be rejected prior to capping, and stoppered vials are protected by grade A air supply until the cap is crimped. The guideline then requires that all filled containers of parenteral products be inspected individually for contamination or other defects, so defective units are detected and removed. A note on terminology: Annex 1 reserves the “100% integrity testing” requirement for containers closed by fusion, such as ampoules and form-fill-seal units; vials and other non-fused systems are verified instead through a validated, risk-based sampling plan. This is also why dimensional consistency in the seal itself matters: a seal that crimps cleanly and repeatably across a high-speed line supports reliable capping and fewer integrity-related rejects. The seal is part of the container closure system that the inspection step is checking.

What Annex 1 means for seal and closure suppliers

Annex 1 legally applies to the manufacturer of the sterile medicine, not to the packaging supplier, but the closures a supplier provides are exactly what the manufacturer depends on to meet the guideline. The drug manufacturer holds the GMP obligation; however, it can only demonstrate container closure integrity if the stoppers and seals it buys are made to consistent, qualified quality.

That is why pharmaceutical buyers expect their primary packaging suppliers to operate a GMP-aligned quality system. The relevant standard for primary packaging manufacturers is ISO 15378, which applies ISO 9001 with GMP requirements specific to materials that contact the medicine. A supplier working to that standard, with controlled production environments and full traceability, gives the drug manufacturer documented confidence that its closures will perform as part of the sterile barrier Annex 1 is concerned with.

How this works in practice at Autofits

Autofits manufactures a range of vial seals and closures, including aluminium-plastic FlipTop® seals, tear-off and tear-down aluminium seals, and aluminium pilfer-proof (ROPP) caps used to seal pharmaceutical vials, including for injectable and vaccine applications. Production runs under an ISO 15378:2017 quality system, alongside ISO 9001:2015 and ISO 14001:2015 certification and a Drug Master File (DMF), in a 75,000 sq ft Nashik facility that includes an ISO Class 8 cleanroom. Sealed units pass through high-speed visual inspection on the closure lines, and the flip-off seal is designed for consistent crimping so it seats reliably during capping. None of this makes Autofits subject to Annex 1, which binds the drug manufacturer, but a GMP-aligned, well-inspected closure is the component a sterile-product manufacturer relies on to support the container closure integrity Annex 1 requires. You can review the full set of certifications on the quality page.

Frequently asked questions

What is EU GMP Annex 1?

EU GMP Annex 1 is the European Union’s Good Manufacturing Practice guideline for the manufacture of sterile medicinal products, such as injectables. It is part of EudraLex Volume 4 and sets out how sterile drugs must be made to control microbial, particulate, and endotoxin contamination. The current 2022 revision came into operation in 2023.

When did the Annex 1 2022 revision take effect?

The revised Annex 1 came into operation on 25 August 2023, with the single exception of the provision relating to lyophilisation, which applied from 25 August 2024. It replaced the previous version of the annex and significantly expanded expectations on contamination control and risk management.

What is a Contamination Control Strategy (CCS) in Annex 1?

A Contamination Control Strategy is a documented, facility-wide plan that defines how a manufacturer controls all sources of microbial, particulate, and endotoxin contamination. Annex 1 makes the CCS a central requirement and expects it to cover facility design, personnel, utilities, raw materials and primary packaging, the process, and the monitoring that confirms control.

How does Annex 1 relate to container closure integrity?

Annex 1 treats container closure integrity as part of sterility assurance: a product is only sterile if its closure keeps the sterile barrier intact over shelf life. The guideline expects capping of filled vials to be controlled, with vials that have missing or displaced stoppers rejected before capping, and it requires every filled parenteral container to be inspected individually for defects. For verifying container closure integrity, Annex 1 requires 100% integrity testing of containers closed by fusion (such as ampoules), while vials and other non-fused systems are checked through a validated, risk-based sampling plan. Integrity is commonly evaluated using methods described in USP <1207>.

Does Annex 1 apply to packaging suppliers?

Annex 1 legally binds the manufacturer of the sterile medicine, not the packaging supplier. However, the stoppers and seals a supplier provides are what the drug manufacturer relies on to demonstrate container closure integrity, so buyers expect their primary packaging suppliers to run a GMP-aligned quality system such as ISO 15378.

Is EU GMP Annex 1 used outside the European Union?

Yes. Although Annex 1 is an EU guideline, it is widely referenced internationally and has been adopted or mirrored by other authorities, including through the PIC/S GMP guide. Many manufacturers supplying multiple regulated markets align their sterile manufacturing to it.

Related reading

Sources

  • European Commission: EudraLex Volume 4, EU GMP guidelines, Annex 1 Manufacture of Sterile Medicinal Products (https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en)
  • ICH: Q9 Quality Risk Management (https://www.ich.org/page/quality-guidelines)
  • USP: United States Pharmacopeia, General Chapter <1207> Package Integrity Evaluation, Sterile Products (https://www.usp.org/)
  • PIC/S: Pharmaceutical Inspection Co-operation Scheme, GMP Guide (https://picscheme.org/)

*Last updated: 2026-06-10. This article is general regulatory information, not legal or compliance advice; confirm current guideline versions with the European Commission and EMA and your own regulatory affairs team.*

Back to top: